Kun Pharmaceutical Group IDH1 selective inhibitors were approved by NMPA clinical trials

Kun Pharmaceutical Group's application for a new drug for IDH1 clinical trials for the self-developed KY100001 tablets, is a specific inhibitor for IDH1 gene mutations of solid tumors, adaptive to IDH1 gene mutations of solid tumors, including but not limited to intra-hepatic bile tube tumors.
IDH is a speed-limiting enzyme involved in cellular energy metabolism in the human body, and studies have shown that intracellular carcinogenic metabolites caused by IDH mutations promote tumor development, while nearly 1/5 of patients with endo-liver bile tube cancer carry IDH1 mutations.
IDH1 inhibitors are being developed worldwide as a high-profile field of anti-tumor drug development.
small molecule IDH1 inhibitor currently on the market is Ivosidenib (AG-120), developed by Agios Pharmaceuticals, to treat recurring or refractic acute myeloid leukemia (AML) adult patients with IDH1 mutations.
KY100001 tablets developed by Kun Pharmaceuticals were approved for clinical trials of drugs, taking the lead in the field of IDH1 inhibitor research and development in China and gaining a leading edge in the segmentation circuit.
is the driving force for the development of pharmaceutical companies.
IDH1 selective inhibitor innovation drug KY100001 research and development is kun medicine in the field of anti-tumor drug research and development strategic layout of one of the important results, at the same time, the company currently has a number of anti-tumor field drug research and development pipeline, for the company's continuous innovation and development to provide new impetus.
In recent years, Kun Medicine has established four major research and development centers in Beijing, Shanghai, North America and Yunnan, creating an efficient international research and development platform and sustainable innovation research and development pipeline, and forming a collaborative development of Chinese medicine, chemical medicine, innovative medicine, independent research and development, external cooperation, investment and mergers and acquisitions multi-channel innovative research and development layout.
, Kun Pharmaceuticals will continue to work deep into the field of cancer treatment, develop innovative drugs, and strive to develop into an innovative, driven international pharmaceutical group focused on the field of libido and the management of chronic diseases.